Supported by grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health to the Data Coordinating Center at New England Research Institutes (HL072268), Case Western Reserve University (HL072033), Children's Hospital Boston (HL072291), Cornell University (HL072196), Duke University (HL072291), Emory University (HL072248), Johns Hopkins University (HL072191), Massachusetts General Hospital (HL072299), Puget Sound Blood Center (HL072305), Tulane (HL072274), University of Iowa (HL072028), University of Maryland (HL072359), University of Minnesota (HL072027), University of North Carolina (HL072355), University of Oklahoma (HL072283), University of Pennsylvania (HL072346), University of Pittsburgh (HL072331), and the Blood Center of Wisconsin (HL072290).
Transfusion-related adverse events in the Platelet Dose study
Article first published online: 28 JUL 2014
© 2014 AABB
Volume 55, Issue 1, pages 144–153, January 2015
How to Cite
Kaufman, R. M., Assmann, S. F., Triulzi, D. J., Strauss, R. G., Ness, P., Granger, S. and Slichter, S. J. (2015), Transfusion-related adverse events in the Platelet Dose study. Transfusion, 55: 144–153. doi: 10.1111/trf.12791
- Issue published online: 13 JAN 2015
- Article first published online: 28 JUL 2014
- Manuscript Accepted: 27 MAY 2014
- Manuscript Revised: 8 MAY 2014
- Manuscript Received: 23 SEP 2013
- New England Research Institutes. Grant Number: HL072268
- CaseWestern Reserve University. Grant Number: HL072033
- Children's Hospital Boston. Grant Number: HL072291
- Cornell University. Grant Number: HL072196
- Duke University. Grant Number: HL072291
- Emory University. Grant Number: HL072248
- Johns Hopkins University. Grant Number: HL072191
- Massachusetts General Hospital. Grant Number: HL072299
- Puget Sound Blood Center. Grant Number: HL072305
- Tulane. Grant Number: HL072274
- University of Iowa. Grant Number: HL072028
- University of Maryland. Grant Number: HL072359
- University of Minnesota. Grant Number: HL072027
- University of North Carolina. Grant Number: HL072355
- University of Oklahoma. Grant Number: HL072283
- University of Pennsylvania. Grant Number: HL072346
- University of Pittsburgh. Grant Number: HL072331
- Blood Center ofWisconsin. Grant Number: HL072290
How platelet (PLT) product characteristics such as dose, source (whole blood derived [WBD] vs. apheresis), storage duration, and ABO matching status affect the risks of transfusion-related adverse events (TRAEs) is unclear. Similarly, more information is needed to define how recipient characteristics affect the frequency of TRAEs after PLT transfusion.
Study Design and Methods
In the multicenter Platelet Dose (“PLADO”) study, pediatric and adult hematology-oncology patients with hypoproliferative thrombocytopenia were randomized to receive low-dose (LD), medium-dose (MD), or high-dose (HD) PLT prophylaxis for a pretransfusion PLT count of not more than 10 × 109/L. All PLT units (apheresis or WBD) were leukoreduced. Post hoc analyses of PLADO data were performed using multipredictor models.
A total of 5034 PLT transfusions to 1102 patients were analyzed. A TRAE occurred with 501 PLT transfusions (10.0%). The most common TRAEs were fever (6.6% of transfusions), allergic or hypersensitivity reactions (1.9%), and sinus tachycardia (1.8%). Patients assigned HD PLTs were more likely than LD or MD patients to experience any TRAE (odds ratio for HD vs. MD, 1.50; 95% confidence interval, 1.10-2.05; three-group comparison p = 0.02). PLT source and ABO matching status were not significantly related to overall TRAE risk. Compared to a patient's first PLT transfusion, subsequent PLT transfusions were less likely to have a TRAE reported, primarily due to a lower risk of allergic or hypersensitivity reactions.
The most important PLT unit characteristic associated with TRAEs was PLT dose per transfusion. HD PLTs may increase the risk of TRAEs, and LD PLTs may reduce the risk.